熱門資訊> 正文

Alvotech利用LOTTE Biologics支持不断增长的生物仿制药产品组合

2026-10-07 04:53

Alvotech (ALVO) announced on Tuesday that it agreed to a long-term deal with LOTTE Biologics to manufacture multiple biosimilar drugs at its Syracuse, New York facility.
The deal adds 40K liters of manufacturing capacity and expands Alvotech’s U.S. production footprint.
The added capacity will support the company's growing biosimilar pipeline and global supply needs, with potential for the partnership to expand.
Moreover, the commercial production will begin after required technology transfer, facility qualification, and regulatory approvals.
Source: Press Release

More on Alvotech

Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alvotech 2026 Q2 - Results - Earnings Call Presentation
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
FDA approves additional U.S. manufacturing capacity for Simlandi, Alvotech’s biosimilar to Humira
Alvotech wins double upgrade at Barclays on upcoming FDA decision

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。